Effect of single dose of rituximab on MPO-ANCA related nephritis

Effect of single dose of rituximab on MPO-ANCA related nephritis - Effect of single dose of rituximab on MPO-ANCA related nephritis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037683

Enrollment

Registered

2019-08-14

Start date

2019-08-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA related nephritis

Interventions

Single dose of rituximab 375mg/m2 (max 500mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases diagnosed by kidney biopsy as MPO-ANCA related rapidly progressive glomerulonephritis (RPGN)

Exclusion criteria

Exclusion criteria: 1. Serious infections 2. Cases of pulmonary involvement 3. Congestive heart failure 4. Malignant tumor patients 5. History of hypersensitivity to rituximab or mouse-derived protein (mouse type, chimeric type, humanized antibody) 6. Complications that may affect the evaluation of this study 7. Other cases considered inappropriate for participation in this study 8. Pregnant women and cases of possible pregnancy

Design outcomes

Primary

Measure	Time frame
BVAS before and after treatment (various imaging tests for evaluation, physiological function tests, etc.) Comparison of histological evaluation in the first and second renal biopsy	—

Countries

Japan

Contacts

Public ContactTaichi Arai

Toho University Dep of Nephro

taichi.arai@med.toho-u.ac.jp81337624151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026